Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer

Phase 1

Withdrawn

Conditions: Stage IVA Colorectal Cancer
Stage IVB Colorectal Cancer

Interventions: Biological: Cetuximab
Drug: Fluorouracil
Drug: Irinotecan Hydrochloride
Drug: Leucovorin Calcium

First Posted Date: 2015-10-09

Last Posted Date: 2016-12-09

Lead Sponsor: University of Chicago

Registration Number: NCT02573220

Locations: 🇮🇹
Centro di Riferimento Oncologico, Aviano, Italy

A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer

Phase 3

Completed

Conditions: Gastric Cancer

Interventions: Drug: Capecitabine
Drug: 5-Fluorouracil
Drug: Cisplatin

First Posted Date: 2015-09-29

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 316

Registration Number: NCT02563054

S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Phase 2

Completed

Conditions: Pancreatic Adenocarcinoma
Resectable Pancreatic Carcinoma

Interventions: Drug: Gemcitabine Hydrochloride
Drug: Fluorouracil
Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Drug: Irinotecan Hydrochloride
Procedure: Pancreatectomy
Drug: Oxaliplatin

First Posted Date: 2015-09-29

Last Posted Date: 2022-10-19

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 147

Registration Number: NCT02562716

Locations: 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Licking Memorial Hospital, Newark, Ohio, United States
🇺🇸
Geisinger Medical Group, State College, Pennsylvania, United States

and more 802 locations

Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer

Phase 2

Active, not recruiting

Conditions: Anal Basaloid Carcinoma
Stage IV Anal Canal Cancer
Recurrent Anal Canal Carcinoma
Anal Squamous Cell Carcinoma
Metastatic Anal Canal Carcinoma
Stage IIIB Anal Canal Cancer
Anal Canal Cloacogenic Carcinoma

Interventions: Drug: Capecitabine
Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Cisplatin
Drug: Fluorouracil
Drug: Paclitaxel
Other: Quality-of-Life Assessment

First Posted Date: 2015-09-25

Last Posted Date: 2023-06-22

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 91

Registration Number: NCT02560298

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma

Phase 1

Completed

Conditions: Skin Neoplasm
Nodular Basal Cell Carcinoma of Skin
Basal Cell Nevus Syndrome

Interventions: Biological: ASN-002
Drug: 5-FU

First Posted Date: 2015-09-15

Last Posted Date: 2018-06-06

Lead Sponsor: Ascend Biopharmaceuticals Ltd

Target Recruit Count: 16

Registration Number: NCT02550678

Locations: 🇦🇺
St George Dermatology and Skin Cancer Centre, Kogarah, New South Wales, Australia
🇦🇺
Siller Medical T/A Central Brisbane Dermatology, Brisbane, Queensland, Australia
🇦🇺
Veracity Clinical Research, Brisbane, Queensland, Australia

and more 1 locations

Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 3

Completed

Conditions: Gastric Adenocarcinoma

Interventions: Drug: Placebo
Drug: Andecaliximab
Drug: Leucovorin
Drug: 5-fluorouracil
Drug: Oxaliplatin

First Posted Date: 2015-09-10

Last Posted Date: 2020-05-26

Lead Sponsor: Gilead Sciences

Target Recruit Count: 432

Registration Number: NCT02545504

Locations: 🇨🇱
Instituto Clinico Oncologico del Sur, Temuco, Chile
🇵🇪
Centro Medico monte Carmelo, Arequipa, Peru
🇦🇺
The Canberra Hospital, Garran, Australian Capital Territory, Australia

and more 131 locations

Effect of Intraoperative Controlled Release 5-Fluorouracil Therapy on Recurrence in Hepatocellular Carcinoma Patients

Not Applicable

Conditions: Recurrence
Hepatocellular Carcinoma

Interventions: Procedure: Hepatectomy
Drug: 5-Fluorouracil

First Posted Date: 2015-08-14

Last Posted Date: 2016-10-21

Lead Sponsor: Eastern Hepatobiliary Surgery Hospital

Target Recruit Count: 160

Registration Number: NCT02523053

Locations: 🇨🇳
Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China

A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab

Phase 2

Conditions: Colorectal Cancer

Interventions: Drug: fluorouracil
Drug: Leucovorin
Drug: irinotecan
Drug: oxaliplatin
Biological: bevacizumab
Biological: cetuximab

First Posted Date: 2015-08-05

Last Posted Date: 2015-08-05

Lead Sponsor: Japan Clinical Cancer Research Organization

Target Recruit Count: 360

Registration Number: NCT02515734

Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus

Phase 3

Active, not recruiting

Conditions: Esophageal Adenocarcinoma (UICC TNM7)
Adenocarcinoma of the Esophagogastric Junction

Interventions: Drug: 5-Fluorouracil
Drug: Carboplatin
Drug: Leucovorin
Drug: Paclitaxel
Radiation: Neoadjuvant radiation
Drug: Oxaliplatin
Drug: Docetaxel

First Posted Date: 2015-07-28

Last Posted Date: 2024-05-08

Lead Sponsor: University Hospital Schleswig-Holstein

Target Recruit Count: 438

Registration Number: NCT02509286

Locations: 🇩🇪
Ruppiner Kliniken GmbH, Neuruppin, Germany
🇩🇪
Klinikum Dortmund gGmbH, Dortmund, Germany
🇩🇪
Uniklinik Köln, Köln, Germany

and more 27 locations

FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer

Phase 2

Terminated

Conditions: Recurrent Colorectal Carcinoma
Stage IVA Colorectal Cancer
Stage IVB Colorectal Cancer

Interventions: Drug: Fluorouracil
Drug: Irinotecan Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Biological: Panitumumab

First Posted Date: 2015-07-24

Last Posted Date: 2018-08-16

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 1

Registration Number: NCT02508077

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
City of Hope Antelope Valley, Lancaster, California, United States
🇺🇸
City of Hope Rancho Cucamonga, Rancho Cucamonga, California, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy